Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients

Perfusion (United Kingdom)

Volumn 29, Issue 5, 2014, Pages 456-461

  Atallah, S ^a,b   Liebl, M ^a   Fitousis, K ^a   Bostan, F ^a   Masud, F ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b SCRIPPS MERCY HOSPITAL   (United States)

Author keywords

activated clotting time; anticoagulation; extracorporeal membrane oxygenation; heparin; partial thromboplastin time

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG MONITORING; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; AGED; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; PHYSIOLOGIC MONITORING; PROCEDURES;

ADULT; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PARTIAL THROMBOPLASTIN TIME; WHOLE BLOOD COAGULATION TIME;

EID: 84921818084     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659114524264     Document Type: Article

References (17)

1. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009 ; 13: 154-175
2. Lequier LL, Annich GM, Massicotte MP ECMO: Extracorporeal Cardiopulmonary Support in Critical Care. 4 th ed.Ann Arbor, MI: Extracorporeal Life Support Organization, 2012, pp. 157-170. Annich GM, ed. Ann Arbor, MI: Extracorporeal Life Support Organization ; 2012: 157-170.
3. Maul TM, Wolff EL, Kuch BA, et al. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2012 ; 13: e363 - e371
4. Bembea MM, Schwartz JM, Shah N, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO Journal. 2013 ; 59: 63-68
5. Rosner B Fundamentals of Biostatistics. Crockett C, ed. Pacific Grove, CA: Duxbury ; 2000: 770.
6. Chan Ak, Leaker M, Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997 ; 77: 270-277 (Pubitemid 27084914)
7. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012 ; 32: 546-558
8. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006 ; 96: 547-552 (Pubitemid 44782532)
9. Scully MF, Decousus HA, Ellis V, et al. Measurement of heparin in plasma: influence of inter-subject and circadian variability in heparin sensitivity according to method. Thromb Res. 1987 ; 46: 447-455 (Pubitemid 17076048)
10. Decousus HA, Croze M, Levi FA, et al. Circadian changes in anticoagulant effect of heparin infused at a constant rate. BMJ. 1985 ; 290: 341-344 (Pubitemid 15115448)
11. Payne S, Mackinnon K, Keeney M, et al. Effect of 3.2% vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low-molecular weight heparin. Clin Lab Haematol. 2003 ; 25: 317-319 (Pubitemid 37211238)
12. Kitchens CS. To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost. 2005 ; 3: 2607-2611 (Pubitemid 41819784)
13. Waele JJ, Cauwenberghe S, Hoste E, et al. The use of the activated clotting time for monitoring heparin therapy in critically ill patients. Intensive Care Med. 2003 ; 29: 325-328 (Pubitemid 36384426)
14. Koerber JM, Smythe MA, Begle RL, et al. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy. 1999 ; 19: 922-931 (Pubitemid 29377310)
15. Smythe MA, Koerbr JM, Nowak SN, et al. Correlation between activated clotting time and activated partial thromboplastin times. Ann Pharmacother. 2003 ; 36: 7-11
16. Atkins BZ, Danielson DS, Fitzpatrick CM, et al. Modified ultrafiltration attenuates pulmonary-derived inflammatory mediators in response to cardiopulmonary bypass. Interact Cardiovasc Thorac Surg. 2010 ; 11: 599-603
17. Ang AL, Teo D, Lim CH, et al. Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation - a single centre experience. Vox Sang. 2009 ; 96: 34-43